factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 935-942 | 935-942 | T46 | markers | PREDISPOSES | 935 | 942 | preserve | 885-888 | 885-888 | T42 | IgE | GeneOrGenome | 885 | 888 | preserve | 959-965 | 959-965 | T45 | asthma | DiseaseOrSyndrome | 959 | 965 | A4 | Serologic assays of specific IgE are specific but insensitive diagnostic markers of diisocyanate asthma. | 856-966 | 856 | 966 | Serologic assays of specific @SUBJECT$ are specific but insensitive diagnostic @PREDICAT$ of diisocyanate @OBJECT$ . |
Fact | preserve | 1584-1587 | 1584-1587 | T92 | for | TREATS | 1,584 | 1,587 | preserve | 1574-1583 | 1574-1583 | T89 | procedure | HealthCareActivity | 1,574 | 1,583 | preserve | 1592-1602 | 1592-1602 | T90 | individual | Human | 1,592 | 1,602 | A1 | This has led to the current practice of a "tailored approach" to reflux disease, in which all patients receive a thorough preoperative physiologic evaluation to determine the best antireflux procedure for the individual. | 1371-1603 | 1,371 | 1,603 | This has led to the current practice of a "tailored approach" to reflux disease, in which all patients receive a thorough preoperative physiologic evaluation to determine the best antireflux @SUBJECT$ @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 954-969 | 965-969 | T57 | reduce the risk | PREVENTS | 954 | 969 | preserve | 816-839 | 824-839 | T46 | partial fundoplications | TherapeuticOrPreventiveProcedure | 816 | 839 | preserve | 978-987 | 978-987 | T53 | dysphasia | MentalOrBehavioralDysfunction | 978 | 987 | A3 | In particular, the use of partial fundoplications in association with Heller's myotomy for achalasia has been demonstrated to be well tolerated and to reduce the risk of late dysphasia resulting from uncontrolled gastroesophageal reflux (GER). | 790-1052 | 790 | 1,052 | In particular, the use of @SUBJECT$ in association with Heller's myotomy for achalasia has been demonstrated to be well tolerated and to @PREDICAT$ of late @OBJECT$ resulting from uncontrolled gastroesophageal reflux (GER). |
Fact | preserve | 1091-1103 | 1095-1103 | T65 | GER patients | PROCESS_OF | 1,091 | 1,103 | preserve | 1091-1094 | 1091-1094 | T60 | GER | DiseaseOrSyndrome | 1,091 | 1,094 | preserve | 1095-1103 | 1095-1103 | T61 | patients | PatientOrDisabledGroup | 1,095 | 1,103 | A4 | The use of partial fundoplications in GER patients with normal motility, however, has been less successful. | 1053-1166 | 1,053 | 1,166 | The use of partial fundoplications in @SUBJECT$ @PREDICAT$ @OBJECT$ with normal motility, however, has been less successful. |
Fact | preserve | 1110-1114 | 1110-1114 | T67 | with | PROCESS_OF | 1,110 | 1,114 | preserve | 1122-1130 | 1122-1130 | T63 | motility | OrganismFunction | 1,122 | 1,130 | preserve | 1095-1103 | 1095-1103 | T61 | patients | PatientOrDisabledGroup | 1,095 | 1,103 | A5 | The use of partial fundoplications in GER patients with normal motility, however, has been less successful. | 1053-1166 | 1,053 | 1,166 | The use of partial fundoplications in GER @OBJECT$ @PREDICAT$ normal @SUBJECT$ , however, has been less successful. |
Fact | preserve | 719-733 | 726-733 | T42 | reflux disease | ISA | 719 | 733 | preserve | 719-725 | 719-725 | T37 | reflux | PathologicFunction | 719 | 725 | preserve | 726-733 | 726-733 | T38 | disease | DiseaseOrSyndrome | 726 | 733 | A6 | These "more physiologic" procedures have proved successful in the treatment of reflux disease in patients with poor or no esophageal motility. | 634-789 | 634 | 789 | These "more physiologic" procedures have proved successful in the treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ in patients with poor or no esophageal motility. |
Fact | preserve | 883-886 | 883-886 | T56 | for | TREATS | 883 | 886 | preserve | 875-882 | 875-882 | T48 | myotomy | TherapeuticOrPreventiveProcedure | 875 | 882 | preserve | 887-896 | 887-896 | T49 | achalasia | Finding | 887 | 896 | A7 | In particular, the use of partial fundoplications in association with Heller's myotomy for achalasia has been demonstrated to be well tolerated and to reduce the risk of late dysphasia resulting from uncontrolled gastroesophageal reflux (GER). | 790-1052 | 790 | 1,052 | In particular, the use of partial fundoplications in association with Heller's @SUBJECT$ @PREDICAT$ @OBJECT$ has been demonstrated to be well tolerated and to reduce the risk of late dysphasia resulting from uncontrolled gastroesophageal reflux (GER). |
Fact | preserve | 719-733 | 726-733 | T44 | reflux disease | PROCESS_OF | 719 | 733 | preserve | 719-725 | 719-725 | T37 | reflux | PathologicFunction | 719 | 725 | preserve | 737-745 | 737-745 | T39 | patients | PatientOrDisabledGroup | 737 | 745 | A8 | These "more physiologic" procedures have proved successful in the treatment of reflux disease in patients with poor or no esophageal motility. | 634-789 | 634 | 789 | These "more physiologic" procedures have proved successful in the treatment of @SUBJECT$ @PREDICAT$ in @OBJECT$ with poor or no esophageal motility. |
Fact | preserve | 248-255 | 248-255 | T15 | therapy | TREATS | 248 | 255 | preserve | 148-188 | 174-188 | T8 | laparoscopic Nissen fundoplication | TherapeuticOrPreventiveProcedure | 148 | 188 | preserve | 266-297 | 290-297 | T14 | gastroesophageal reflux disease | DiseaseOrSyndrome | 266 | 297 | A9 | The Nissen fundoplication, and in particular the laparoscopic Nissen fundoplication, has received widespread acceptance as the most definitive therapy for gastroesophageal reflux disease. | 99-298 | 99 | 298 | The Nissen fundoplication, and in particular the @SUBJECT$ , has received widespread acceptance as the most definitive @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 1088-1090 | 1088-1090 | T66 | in | TREATS | 1,088 | 1,090 | preserve | 1064-1087 | 1072-1087 | T59 | partial fundoplications | TherapeuticOrPreventiveProcedure | 1,064 | 1,087 | preserve | 1091-1094 | 1091-1094 | T60 | GER | DiseaseOrSyndrome | 1,091 | 1,094 | A10 | The use of partial fundoplications in GER patients with normal motility, however, has been less successful. | 1053-1166 | 1,053 | 1,166 | The use of @SUBJECT$ @PREDICAT$ @OBJECT$ patients with normal motility, however, has been less successful. |
Fact | preserve | 1442-1456 | 1449-1456 | T91 | reflux disease | ISA | 1,442 | 1,456 | preserve | 1442-1448 | 1442-1448 | T84 | reflux | PathologicFunction | 1,442 | 1,448 | preserve | 1449-1456 | 1449-1456 | T85 | disease | DiseaseOrSyndrome | 1,449 | 1,456 | A11 | This has led to the current practice of a "tailored approach" to reflux disease, in which all patients receive a thorough preoperative physiologic evaluation to determine the best antireflux procedure for the individual. | 1371-1603 | 1,371 | 1,603 | This has led to the current practice of a "tailored approach" to @SUBJECT$ @PREDICAT$ @OBJECT$ , in which all patients receive a thorough preoperative physiologic evaluation to determine the best antireflux procedure for the individual. |
Fact | preserve | 24-27 | 24-27 | T6 | for | TREATS | 24 | 27 | preserve | 0-23 | 8-23 | T1 | Partial fundoplications | TherapeuticOrPreventiveProcedure | 0 | 23 | preserve | 28-59 | 52-59 | T2 | gastroesophageal reflux disease | DiseaseOrSyndrome | 28 | 59 | A12 | Partial fundoplications for gastroesophageal reflux disease: indications and current status. | 0-98 | 0 | 98 | @SUBJECT$ @PREDICAT$ @OBJECT$ : indications and current status. |
Fact | preserve | 383-404 | 392-404 | T23 | surgical augmentation | ISA | 383 | 404 | preserve | 392-404 | 392-404 | T20 | augmentation | TherapeuticOrPreventiveProcedure | 392 | 404 | preserve | 383-391 | 383-391 | T19 | surgical | TherapeuticOrPreventiveProcedure | 383 | 391 | A13 | There remains, however, certain patients who do better with a less aggressive surgical augmentation of the lower esophageal sphincter. | 299-445 | 299 | 445 | There remains, however, certain patients who do better with a less aggressive @OBJECT$ @PREDICAT$ @SUBJECT$ of the lower esophageal sphincter. |
Fact | preserve | 1088-1090 | 1088-1090 | T66 | in | TREATS | 1,088 | 1,090 | preserve | 1064-1087 | 1072-1087 | T59 | partial fundoplications | TherapeuticOrPreventiveProcedure | 1,064 | 1,087 | preserve | 1095-1103 | 1095-1103 | T61 | patients | PatientOrDisabledGroup | 1,095 | 1,103 | A14 | The use of partial fundoplications in GER patients with normal motility, however, has been less successful. | 1053-1166 | 1,053 | 1,166 | The use of @SUBJECT$ @PREDICAT$ GER @OBJECT$ with normal motility, however, has been less successful. |
Fact | preserve | 734-736 | 734-736 | T43 | in | PROCESS_OF | 734 | 736 | preserve | 726-733 | 726-733 | T38 | disease | DiseaseOrSyndrome | 726 | 733 | preserve | 737-745 | 737-745 | T39 | patients | PatientOrDisabledGroup | 737 | 745 | A15 | These "more physiologic" procedures have proved successful in the treatment of reflux disease in patients with poor or no esophageal motility. | 634-789 | 634 | 789 | These "more physiologic" procedures have proved successful in the treatment of reflux @SUBJECT$ @PREDICAT$ @OBJECT$ with poor or no esophageal motility. |
Fact | preserve | 925-937 | 925-937 | T59 | pathogenesis | CAUSES | 925 | 937 | preserve | 839-853 | 839-853 | T53 | autoantibodies | AminoAcidPeptideOrProtein | 839 | 853 | preserve | 947-953 | 947-953 | T57 | asthma | DiseaseOrSyndrome | 947 | 953 | A1 | This experiment suggests that the autoantibodies to beta 2-adrenergic receptors may play an important role in the pathogenesis of asthma. | 805-954 | 805 | 954 | This experiment suggests that the @SUBJECT$ to beta 2-adrenergic receptors may play an important role in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 592-596 | 592-596 | T46 | with | PROCESS_OF | 592 | 596 | preserve | 597-603 | 597-603 | T38 | asthma | DiseaseOrSyndrome | 597 | 603 | preserve | 583-591 | 583-591 | T37 | patients | PatientOrDisabledGroup | 583 | 591 | A4 | In the sera of all patients with asthma (16 cases) there were autoantibodies to beta 2-adrenergic receptors, but not in the normal controls (20 cases). | 564-727 | 564 | 727 | In the sera of all @OBJECT$ @PREDICAT$ @SUBJECT$ (16 cases) there were autoantibodies to beta 2-adrenergic receptors, but not in the normal controls (20 cases). |
Fact | preserve | 266-321 | 310-321 | T22 | beta 2-selective adrenergic agonist, clenbuterol | ISA | 266 | 321 | preserve | 310-321 | 310-321 | T17 | clenbuterol | OrganicChemical | 310 | 321 | preserve | 266-308 | 301-308 | T16 | beta 2-selective adrenergic agonist | PharmacologicSubstance | 266 | 308 | A5 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of beta 2-selective adrenergic agonist, clenbuterol, on cultured neonatal rat cardiomyocytes. | 104-369 | 104 | 369 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of @OBJECT$ @PREDICAT$ @SUBJECT$ , on cultured neonatal rat cardiomyocytes. |
Fact | preserve | 323-325 | 323-325 | T25 | on | LOCATION_OF | 323 | 325 | preserve | 354-368 | 354-368 | T21 | cardiomyocytes | Cell | 354 | 368 | preserve | 310-321 | 310-321 | T17 | clenbuterol | OrganicChemical | 310 | 321 | A6 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of beta 2-selective adrenergic agonist, clenbuterol, on cultured neonatal rat cardiomyocytes. | 104-369 | 104 | 369 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of beta 2-selective adrenergic agonist, @OBJECT$ , @PREDICAT$ cultured neonatal rat @SUBJECT$ . |
Fact | preserve | 344-368 | 354-368 | T24 | rat cardiomyocytes | PART_OF | 344 | 368 | preserve | 354-368 | 354-368 | T21 | cardiomyocytes | Cell | 354 | 368 | preserve | 344-347 | 344-347 | T20 | rat | Mammal | 344 | 347 | A7 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of beta 2-selective adrenergic agonist, clenbuterol, on cultured neonatal rat cardiomyocytes. | 104-369 | 104 | 369 | To understand the roles of autoantibodies to beta 2 adrenergic receptors in the pathogenesis of asthma, we investigated the positive chronotropic action of beta 2-selective adrenergic agonist, clenbuterol, on cultured neonatal @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 90-94 | 90-94 | T8 | with | PROCESS_OF | 90 | 94 | preserve | 95-101 | 95-101 | T6 | asthma | DiseaseOrSyndrome | 95 | 101 | preserve | 81-89 | 81-89 | T5 | patients | PatientOrDisabledGroup | 81 | 89 | A8 | [Detection of circulating autoantibodies to beta 2-adrenergic receptors in patients with asthma]. | 0-103 | 0 | 103 | [Detection of circulating autoantibodies to beta 2-adrenergic receptors in @OBJECT$ @PREDICAT$ @SUBJECT$ ]. |
Fact | preserve | 476-480 | 476-480 | T35 | with | PROCESS_OF | 476 | 480 | preserve | 481-487 | 481-487 | T30 | asthma | DiseaseOrSyndrome | 481 | 487 | preserve | 467-475 | 467-475 | T29 | patients | PatientOrDisabledGroup | 467 | 475 | A12 | Thereafter, we detected the autoantibodies to beta 2-adrenergic receptors in the sera from patients with asthma as it could inhibit the positive chronotropic action of clenbuterol. | 370-563 | 370 | 563 | Thereafter, we detected the autoantibodies to beta 2-adrenergic receptors in the sera from @OBJECT$ @PREDICAT$ @SUBJECT$ as it could inhibit the positive chronotropic action of clenbuterol. |
Possible | preserve | 1518-1527 | 1518-1527 | T87 | treatment | TREATS | 1,518 | 1,527 | preserve | 1433-1437 | 1433-1437 | T81 | AO-8 | TherapeuticOrPreventiveProcedure | 1,433 | 1,437 | preserve | 1545-1554 | 1545-1554 | T85 | disorders | DiseaseOrSyndrome | 1,545 | 1,554 | A1 | Thus it can be concluded that AO-8 is an effective free radical scavenger and could prove beneficial in the treatment of various disorders associated with the involvement of free radicals. | 1403-1604 | 1,403 | 1,604 | Thus it can be concluded that @SUBJECT$ is an effective free radical scavenger and could prove beneficial in the @PREDICAT$ of various @OBJECT$ associated with the involvement of free radicals. |
Fact | preserve | 543-552 | 549-552 | T43 | serum GOT | LOCATION_OF | 543 | 552 | preserve | 543-548 | 543-548 | T33 | serum | BodySubstance | 543 | 548 | preserve | 549-552 | 549-552 | T34 | GOT | AminoAcidPeptideOrProtein | 549 | 552 | A2 | The levels of serum GOT and LDH, cardiac glutathione, SOD and catalase were estimated following induction of myocardial infarction with isoproterenol. | 529-685 | 529 | 685 | The levels of @SUBJECT$ @PREDICAT$ @OBJECT$ and LDH, cardiac glutathione, SOD and catalase were estimated following induction of myocardial infarction with isoproterenol. |
Uncommitted | preserve | 435-437 | 435-437 | T30 | in | TREATS | 435 | 437 | preserve | 361-365 | 361-365 | T20 | AO-8 | TherapeuticOrPreventiveProcedure | 361 | 365 | preserve | 460-481 | 471-481 | T25 | myocardial infarction | DiseaseOrSyndrome | 460 | 481 | A5 | in isoproterenol-induced myocardial infarction and CCl4-induced hepatotoxicity in rats. | 435-528 | 435 | 528 | in isoproterenol-in @SUBJECT$ @PREDICAT$ isoproterenol-induced @OBJECT$ and CCl4-induced hepatotoxicity in rats. |
Fact | preserve | 294-301 | 294-301 | T19 | induced | AUGMENTS | 294 | 301 | preserve | 283-293 | 290-293 | T15 | ferric ion | BiologicallyActiveSubstance | 283 | 293 | preserve | 302-320 | 308-320 | T16 | lipid peroxidation | MolecularFunction | 302 | 320 | A6 | AO-8 dose dependently inhibited ferric ion induced lipid peroxidation in vitro at 125-1000 micrograms. | 245-360 | 245 | 360 | AO-8 dose dependently inhibited @SUBJECT$ @PREDICAT$ @OBJECT$ in vitro at 125-1000 micrograms. |
Uncommitted | preserve | 435-437 | 435-437 | T30 | in | TREATS | 435 | 437 | preserve | 361-365 | 361-365 | T20 | AO-8 | TherapeuticOrPreventiveProcedure | 361 | 365 | preserve | 499-513 | 499-513 | T28 | hepatotoxicity | InjuryOrPoisoning | 499 | 513 | A7 | in isoproterenol-induced myocardial infarction and CCl4-induced hepatotoxicity in rats. | 435-528 | 435 | 528 | in isoproterenol-in @SUBJECT$ @PREDICAT$ isoproterenol-induced myocardial infarction and CCl4-induced @OBJECT$ in rats. |
Fact | preserve | 631-640 | 631-640 | T44 | induction | CAUSES | 631 | 640 | preserve | 671-684 | 671-684 | T42 | isoproterenol | OrganicChemical | 671 | 684 | preserve | 644-665 | 655-665 | T41 | myocardial infarction | DiseaseOrSyndrome | 644 | 665 | A8 | The levels of serum GOT and LDH, cardiac glutathione, SOD and catalase were estimated following induction of myocardial infarction with isoproterenol. | 529-685 | 529 | 685 | The levels of serum GOT and LDH, cardiac glutathione, SOD and catalase were estimated following @PREDICAT$ of @OBJECT$ with @SUBJECT$ . |
Fact | preserve | 1955-1957 | 1955-1957 | T107 | in | TREATS | 1,955 | 1,957 | preserve | 1942-1948 | 1942-1948 | T103 | DMARDs | PharmacologicSubstance | 1,942 | 1,948 | preserve | 1972-1992 | 1983-1992 | T105 | rheumatoid arthritis | DiseaseOrSyndrome | 1,972 | 1,992 | A1 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with DMARDs in patients with rheumatoid arthritis. | 1867-1993 | 1,867 | 1,993 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with @SUBJECT$ @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1066-1068 | 1066-1068 | T65 | in | PROCESS_OF | 1,066 | 1,068 | preserve | 1051-1060 | 1051-1060 | T60 | apoptosis | CellFunction | 1,051 | 1,060 | preserve | 1073-1081 | 1073-1081 | T61 | patients | PatientOrDisabledGroup | 1,073 | 1,081 | A2 | Immunomodulatory effects were investigated by measuring lymphocyte proliferation and apoptosis both in the patients and in vitro in 10 nM alphacalcidiol-supplemented culture medium. | 960-1153 | 960 | 1,153 | Immunomodulatory effects were investigated by measuring lymphocyte proliferation and @SUBJECT$ both @PREDICAT$ the @OBJECT$ and in vitro in 10 nM alphacalcidiol-supplemented culture medium. |
Fact | preserve | 1066-1068 | 1066-1068 | T65 | in | PROCESS_OF | 1,066 | 1,068 | preserve | 1022-1046 | 1033-1046 | T59 | lymphocyte proliferation | CellFunction | 1,022 | 1,046 | preserve | 1073-1081 | 1073-1081 | T61 | patients | PatientOrDisabledGroup | 1,073 | 1,081 | A3 | Immunomodulatory effects were investigated by measuring lymphocyte proliferation and apoptosis both in the patients and in vitro in 10 nM alphacalcidiol-supplemented culture medium. | 960-1153 | 960 | 1,153 | Immunomodulatory effects were investigated by measuring @SUBJECT$ and apoptosis both @PREDICAT$ the @OBJECT$ and in vitro in 10 nM alphacalcidiol-supplemented culture medium. |
Fact | preserve | 1955-1957 | 1955-1957 | T107 | in | TREATS | 1,955 | 1,957 | preserve | 1942-1948 | 1942-1948 | T103 | DMARDs | PharmacologicSubstance | 1,942 | 1,948 | preserve | 1958-1966 | 1958-1966 | T104 | patients | PatientOrDisabledGroup | 1,958 | 1,966 | A4 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with DMARDs in patients with rheumatoid arthritis. | 1867-1993 | 1,867 | 1,993 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with @SUBJECT$ @PREDICAT$ @OBJECT$ with rheumatoid arthritis. |
Fact | preserve | 750-762 | 755-762 | T47 | drug regimen | USES | 750 | 762 | preserve | 755-762 | 755-762 | T42 | regimen | ResearchActivity | 755 | 762 | preserve | 750-754 | 750-754 | T41 | drug | PharmacologicSubstance | 750 | 754 | A6 | Their regular drug regimen was maintained during the trial and oral alphacalcidiol 2 micrograms/day was added. | 736-852 | 736 | 852 | Their regular @OBJECT$ @PREDICAT$ @SUBJECT$ was maintained during the trial and oral alphacalcidiol 2 micrograms/day was added. |
Fact | preserve | 601-614 | 607-614 | T36 | DMARD therapy | USES | 601 | 614 | preserve | 607-614 | 607-614 | T32 | therapy | TherapeuticOrPreventiveProcedure | 607 | 614 | preserve | 601-606 | 601-606 | T31 | DMARD | PharmacologicSubstance | 601 | 606 | A7 | METHODS: We organized a 3-month open-label trial on 19 patients being treated with standard DMARD therapy for acute RA. | 497-628 | 497 | 628 | METHODS: We organized a 3-month open-label trial on 19 patients being treated with standard @OBJECT$ @PREDICAT$ @SUBJECT$ for acute RA. |
Fact | preserve | 1967-1971 | 1967-1971 | T108 | with | PROCESS_OF | 1,967 | 1,971 | preserve | 1972-1992 | 1983-1992 | T105 | rheumatoid arthritis | DiseaseOrSyndrome | 1,972 | 1,992 | preserve | 1958-1966 | 1958-1966 | T104 | patients | PatientOrDisabledGroup | 1,958 | 1,966 | A9 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with DMARDs in patients with rheumatoid arthritis. | 1867-1993 | 1,867 | 1,993 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with DMARDs in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 85-114 | 106-114 | T9 | rheumatoid arthritis patients | PROCESS_OF | 85 | 114 | preserve | 85-105 | 96-105 | T7 | rheumatoid arthritis | DiseaseOrSyndrome | 85 | 105 | preserve | 106-114 | 106-114 | T8 | patients | PatientOrDisabledGroup | 106 | 114 | A10 | Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. | 0-115 | 0 | 115 | Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 470-474 | 470-474 | T23 | with | PROCESS_OF | 470 | 474 | preserve | 475-495 | 486-495 | T21 | rheumatoid arthritis | DiseaseOrSyndrome | 475 | 495 | preserve | 461-469 | 461-469 | T20 | patients | PatientOrDisabledGroup | 461 | 469 | A11 | Experimentally established possibilities to prevent autoimmune diseases suggest that alphacalcidiol may have therapeutic value as an immunomodulatory agent in patients with rheumatoid arthritis. | 290-496 | 290 | 496 | Experimentally established possibilities to prevent autoimmune diseases suggest that alphacalcidiol may have therapeutic value as an immunomodulatory agent in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1937-1941 | 1937-1941 | T106 | with | USES | 1,937 | 1,941 | preserve | 1929-1936 | 1929-1936 | T102 | therapy | TherapeuticOrPreventiveProcedure | 1,929 | 1,936 | preserve | 1942-1948 | 1942-1948 | T103 | DMARDs | PharmacologicSubstance | 1,942 | 1,948 | A12 | Alphacalcidiol could therefore possibly be used as an adjunct therapy with DMARDs in patients with rheumatoid arthritis. | 1867-1993 | 1,867 | 1,993 | Alphacalcidiol could therefore possibly be used as an adjunct @SUBJECT$ @PREDICAT$ @OBJECT$ in patients with rheumatoid arthritis. |
Fact | preserve | 573-580 | 573-580 | T35 | treated | TREATS | 573 | 580 | preserve | 607-614 | 607-614 | T32 | therapy | TherapeuticOrPreventiveProcedure | 607 | 614 | preserve | 558-566 | 558-566 | T29 | patients | PatientOrDisabledGroup | 558 | 566 | A13 | METHODS: We organized a 3-month open-label trial on 19 patients being treated with standard DMARD therapy for acute RA. | 497-628 | 497 | 628 | METHODS: We organized a 3-month open-label trial on 19 @OBJECT$ being @PREDICAT$ with standard DMARD @SUBJECT$ for acute RA. |
Fact | preserve | 2053-2057 | 2053-2057 | T109 | with | PROCESS_OF | 2,053 | 2,057 | preserve | 2058-2088 | 2080-2088 | T105 | type 2 diabetes mellitus | DiseaseOrSyndrome | 2,058 | 2,088 | preserve | 2044-2052 | 2044-2052 | T104 | patients | PatientOrDisabledGroup | 2,044 | 2,052 | A1 | The vast majority of patients with type 2 diabetes mellitus can undertake an individualised exercise programme without significantly increased risks of complications. | 2023-2201 | 2,023 | 2,201 | The vast majority of @OBJECT$ @PREDICAT$ @SUBJECT$ can undertake an individualised exercise programme without significantly increased risks of complications. |
Fact | preserve | 1040-1044 | 1040-1044 | T62 | with | PROCESS_OF | 1,040 | 1,044 | preserve | 1045-1075 | 1067-1075 | T56 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,045 | 1,075 | preserve | 1031-1039 | 1031-1039 | T55 | patients | PatientOrDisabledGroup | 1,031 | 1,039 | A2 | There has been little research into the effects of resistance training on glucose metabolism in patients with type 2 diabetes mellitus compared with the amount of research involving aerobic endurance exercise. | 929-1156 | 929 | 1,156 | There has been little research into the effects of resistance training on glucose metabolism in @OBJECT$ @PREDICAT$ @SUBJECT$ compared with the amount of research involving aerobic endurance exercise. |
Uncommitted | preserve | 1028-1030 | 1028-1030 | T61 | in | TREATS | 1,028 | 1,030 | preserve | 986-1005 | 997-1005 | T53 | resistance training | TherapeuticOrPreventiveProcedure | 986 | 1,005 | preserve | 1045-1075 | 1067-1075 | T56 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,045 | 1,075 | A3 | There has been little research into the effects of resistance training on glucose metabolism in patients with type 2 diabetes mellitus compared with the amount of research involving aerobic endurance exercise. | 929-1156 | 929 | 1,156 | There has been little research into the effects of @SUBJECT$ on glucose metabolism @PREDICAT$ patients with @OBJECT$ compared with the amount of research involving aerobic endurance exercise. |
Fact | preserve | 666-670 | 666-670 | T47 | with | PROCESS_OF | 666 | 670 | preserve | 671-695 | 687-695 | T37 | type 2 diabetes mellitus | DiseaseOrSyndrome | 671 | 695 | preserve | 657-665 | 657-665 | T36 | patients | PatientOrDisabledGroup | 657 | 665 | A4 | patients with type 2 diabetes mellitus under 55 years of age, those with diabetes treated through diet and those who have diabetes with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. | 657-928 | 657 | 928 | @OBJECT$ @PREDICAT$ @SUBJECT$ under 55 years of age, those with diabetes treated through diet and those who have diabetes with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. |
Probable | preserve | 1498-1507 | 1498-1507 | T79 | treatment | TREATS | 1,498 | 1,507 | preserve | 1465-1490 | 1482-1490 | T76 | resistance training | TherapeuticOrPreventiveProcedure | 1,465 | 1,490 | preserve | 1511-1535 | 1527-1535 | T78 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,511 | 1,535 | A5 | Available studies support the usefulness of resistance training in the treatment of type 2 diabetes mellitus. | 1421-1536 | 1,421 | 1,536 | Available studies support the usefulness of @SUBJECT$ in the @PREDICAT$ of @OBJECT$ . |
Uncommitted | preserve | 1028-1030 | 1028-1030 | T61 | in | TREATS | 1,028 | 1,030 | preserve | 986-1005 | 997-1005 | T53 | resistance training | TherapeuticOrPreventiveProcedure | 986 | 1,005 | preserve | 1031-1039 | 1031-1039 | T55 | patients | PatientOrDisabledGroup | 1,031 | 1,039 | A6 | There has been little research into the effects of resistance training on glucose metabolism in patients with type 2 diabetes mellitus compared with the amount of research involving aerobic endurance exercise. | 929-1156 | 929 | 1,156 | There has been little research into the effects of @SUBJECT$ on glucose metabolism @PREDICAT$ @OBJECT$ with type 2 diabetes mellitus compared with the amount of research involving aerobic endurance exercise. |
Fact | preserve | 780-784 | 780-784 | T49 | have | PROCESS_OF | 780 | 784 | preserve | 785-793 | 785-793 | T42 | diabetes | DiseaseOrSyndrome | 785 | 793 | preserve | 657-665 | 657-665 | T36 | patients | PatientOrDisabledGroup | 657 | 665 | A7 | patients with type 2 diabetes mellitus under 55 years of age, those with diabetes treated through diet and those who have diabetes with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. | 657-928 | 657 | 928 | @OBJECT$ with type 2 diabetes mellitus under 55 years of age, those with diabetes treated through diet and those who @PREDICAT$ @SUBJECT$ with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. |
Fact | preserve | 1673-1677 | 1673-1677 | T97 | with | PROCESS_OF | 1,673 | 1,677 | preserve | 1678-1702 | 1694-1702 | T85 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,678 | 1,702 | preserve | 1661-1672 | 1661-1672 | T84 | individuals | Human | 1,661 | 1,672 | A9 | Therefore, based on the published studies reviewed, this author proposes that an optimal exercise programme for individuals with type 2 diabetes mellitus should include components that improve cardiorespiratory fitness, muscular strength and endurance, i.e. | 1537-1812 | 1,537 | 1,812 | Therefore, based on the published studies reviewed, this author proposes that an optimal exercise programme for @OBJECT$ @PREDICAT$ @SUBJECT$ should include components that improve cardiorespiratory fitness, muscular strength and endurance, i.e. |
Fact | preserve | 140-143 | 140-143 | T11 | for | TREATS | 140 | 143 | preserve | 122-139 | 132-139 | T7 | treatment regimen | ResearchActivity | 122 | 139 | preserve | 150-158 | 150-158 | T8 | patients | PatientOrDisabledGroup | 150 | 158 | A10 | Exercise has long been considered a cornerstone in the treatment regimen for patients with type 2 (non-insulin-dependent) diabetes mellitus. | 67-213 | 67 | 213 | Exercise has long been considered a cornerstone in the @SUBJECT$ @PREDICAT$ @OBJECT$ with type 2 (non-insulin-dependent) diabetes mellitus. |
Fact | preserve | 731-735 | 731-735 | T48 | with | PROCESS_OF | 731 | 735 | preserve | 736-744 | 736-744 | T40 | diabetes | DiseaseOrSyndrome | 736 | 744 | preserve | 657-665 | 657-665 | T36 | patients | PatientOrDisabledGroup | 657 | 665 | A13 | patients with type 2 diabetes mellitus under 55 years of age, those with diabetes treated through diet and those who have diabetes with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. | 657-928 | 657 | 928 | @OBJECT$ with type 2 diabetes mellitus under 55 years of age, those @PREDICAT$ @SUBJECT$ treated through diet and those who have diabetes with fairly good metabolic control), does exercise seem to be beneficial with regard to improvement in glycaemic control. |
Fact | preserve | 821-829 | 821-829 | T57 | presence | COEXISTS_WITH | 821 | 829 | preserve | 748-752 | 748-752 | T51 | DSCG | OrganicChemical | 748 | 752 | preserve | 875-885 | 875-885 | T55 | reproterol | OrganicChemical | 875 | 885 | A1 | Mast cell stabilization by DSCG (1-100 microM) was strongly and significantly enhanced in the presence of a fixed saturating concentration of reproterol (100 microM). | 721-899 | 721 | 899 | Mast cell stabilization by @SUBJECT$ (1-100 microM) was strongly and significantly enhanced in the @PREDICAT$ of a fixed saturating concentration of @OBJECT$ (100 microM). |
Fact | preserve | 614-628 | 623-628 | T47 | rat mast cells | PART_OF | 614 | 628 | preserve | 618-628 | 623-628 | T39 | mast cells | Cell | 618 | 628 | preserve | 614-617 | 614-617 | T38 | rat | Mammal | 614 | 617 | A3 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | Reproterol was as potent as DSCG to inhibit histamine release in @OBJECT$ @PREDICAT$ @SUBJECT$ (32.8+/-6.0 vs. |
Fact | preserve | 567-569 | 567-569 | T43 | as | compared_with | 567 | 569 | preserve | 542-552 | 542-552 | T34 | Reproterol | OrganicChemical | 542 | 552 | preserve | 570-574 | 570-574 | T36 | DSCG | OrganicChemical | 570 | 574 | A8 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | @SUBJECT$ was as potent @PREDICAT$ @OBJECT$ to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. |
Fact | preserve | 220-229 | 220-229 | T19 | treatment | TREATS | 220 | 229 | preserve | 132-142 | 132-142 | T10 | reproterol | OrganicChemical | 132 | 142 | preserve | 233-239 | 233-239 | T15 | asthma | DiseaseOrSyndrome | 233 | 239 | A10 | The beta2-adrenoceptor agonist reproterol and disodium cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively. | 101-328 | 101 | 328 | The beta2-adrenoceptor agonist @SUBJECT$ and disodium cromoglycate (DSCG) are used in fixed combination for the @PREDICAT$ of @OBJECT$ , because they act on bronchial smooth muscle and inflammatory cells, respectively. |
Fact | preserve | 578-585 | 578-585 | T45 | inhibit | DISRUPTS | 578 | 585 | preserve | 570-574 | 570-574 | T36 | DSCG | OrganicChemical | 570 | 574 | preserve | 586-610 | 603-610 | T37 | histamine release | CellFunction | 586 | 610 | A11 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | Reproterol was as potent as @SUBJECT$ to @PREDICAT$ @OBJECT$ in rat mast cells (32.8+/-6.0 vs. |
Fact | preserve | 916-927 | 916-927 | T74 | combination | COEXISTS_WITH | 916 | 927 | preserve | 973-980 | 973-980 | T62 | agonist | PharmacologicSubstance | 973 | 980 | preserve | 938-942 | 938-942 | T59 | DSCG | OrganicChemical | 938 | 942 | A12 | Conversely, the combination of DSCG (1-100 microM) with the beta2-agonist used as reference compound, salbutamol (100 microM) did not inhibit histamine release more than DSCG alone. | 900-1094 | 900 | 1,094 | Conversely, the @PREDICAT$ of @OBJECT$ (1-100 microM) with the beta2- @SUBJECT$ used as reference compound, salbutamol (100 microM) did not inhibit histamine release more than DSCG alone. |
Fact | preserve | 1698-1712 | 1707-1712 | T123 | rat mast cells | PART_OF | 1,698 | 1,712 | preserve | 1702-1712 | 1707-1712 | T121 | mast cells | Cell | 1,702 | 1,712 | preserve | 1698-1701 | 1698-1701 | T120 | rat | Mammal | 1,698 | 1,701 | A16 | In conclusion, reproterol enhances the ability of disodium cromoglycate to stabilize rat mast cells. | 1607-1713 | 1,607 | 1,713 | In conclusion, reproterol enhances the ability of disodium cromoglycate to stabilize @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 387-401 | 396-401 | T31 | rat mast cells | PART_OF | 387 | 401 | preserve | 391-401 | 396-401 | T24 | mast cells | Cell | 391 | 401 | preserve | 387-390 | 387-390 | T23 | rat | Mammal | 387 | 390 | A17 | Here, we investigated if reproterol can also act in rat mast cells in vitro to facilitate the inhibitory action of disodium cromoglycate (DSCG) on histamine secretion induced by compound 48/80. | 329-541 | 329 | 541 | Here, we investigated if reproterol can also act in @OBJECT$ @PREDICAT$ @SUBJECT$ in vitro to facilitate the inhibitory action of disodium cromoglycate (DSCG) on histamine secretion induced by compound 48/80. |
Fact | preserve | 85-99 | 89-99 | T7 | rat mastocytes | PART_OF | 85 | 99 | preserve | 89-99 | 89-99 | T5 | mastocytes | Cell | 89 | 99 | preserve | 85-88 | 85-88 | T4 | rat | Mammal | 85 | 88 | A19 | Enhancement by reproterol of the ability of disodium cromoglycate to stabilize rat mastocytes. | 0-100 | 0 | 100 | Enhancement by reproterol of the ability of disodium cromoglycate to stabilize @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1591-1605 | 1600-1605 | T114 | rat mast cells | PART_OF | 1,591 | 1,605 | preserve | 1595-1605 | 1600-1605 | T111 | mast cells | Cell | 1,595 | 1,605 | preserve | 1591-1594 | 1591-1594 | T110 | rat | Mammal | 1,591 | 1,594 | A20 | Finally, the phosphodiesterase inhibitor theophylline (100 microM) was equipotent to reproterol and DSCG in stabilizing rat mast cells. | 1464-1606 | 1,464 | 1,606 | Finally, the phosphodiesterase inhibitor theophylline (100 microM) was equipotent to reproterol and DSCG in stabilizing @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1181-1190 | 1181-1190 | T88 | inhibited | INHIBITS | 1,181 | 1,190 | preserve | 1164-1174 | 1164-1174 | T81 | reproterol | OrganicChemical | 1,164 | 1,174 | preserve | 1191-1200 | 1191-1200 | T82 | histamine | NeuroreactiveSubstanceOrBiogenicAmine | 1,191 | 1,200 | A21 | In combination with a saturating concentration of DSCG (100 microM), reproterol inhibited histamine release more than reproterol alone. | 1095-1236 | 1,095 | 1,236 | In combination with a saturating concentration of DSCG (100 microM), @SUBJECT$ @PREDICAT$ @OBJECT$ release more than reproterol alone. |
Fact | preserve | 578-585 | 578-585 | T45 | inhibit | DISRUPTS | 578 | 585 | preserve | 542-552 | 542-552 | T34 | Reproterol | OrganicChemical | 542 | 552 | preserve | 586-610 | 603-610 | T37 | histamine release | CellFunction | 586 | 610 | A23 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | @SUBJECT$ was as potent as DSCG to @PREDICAT$ @OBJECT$ in rat mast cells (32.8+/-6.0 vs. |
Fact | preserve | 0-11 | 0-11 | T6 | Enhancement | STIMULATES | 0 | 11 | preserve | 15-25 | 15-25 | T1 | reproterol | OrganicChemical | 15 | 25 | preserve | 44-65 | 53-65 | T3 | disodium cromoglycate | OrganicChemical | 44 | 65 | A24 | Enhancement by reproterol of the ability of disodium cromoglycate to stabilize rat mastocytes. | 0-100 | 0 | 100 | @PREDICAT$ by @SUBJECT$ of the ability of @OBJECT$ to stabilize rat mastocytes. |
Fact | preserve | 611-613 | 611-613 | T48 | in | LOCATION_OF | 611 | 613 | preserve | 618-628 | 623-628 | T39 | mast cells | Cell | 618 | 628 | preserve | 586-610 | 603-610 | T37 | histamine release | CellFunction | 586 | 610 | A25 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | Reproterol was as potent as DSCG to inhibit @OBJECT$ @PREDICAT$ rat @SUBJECT$ (32.8+/-6.0 vs. |
Fact | preserve | 1477-1517 | 1505-1517 | T112 | phosphodiesterase inhibitor theophylline | ISA | 1,477 | 1,517 | preserve | 1505-1517 | 1505-1517 | T105 | theophylline | BiologicallyActiveSubstance | 1,505 | 1,517 | preserve | 1477-1504 | 1495-1504 | T104 | phosphodiesterase inhibitor | PharmacologicSubstance | 1,477 | 1,504 | A26 | Finally, the phosphodiesterase inhibitor theophylline (100 microM) was equipotent to reproterol and DSCG in stabilizing rat mast cells. | 1464-1606 | 1,464 | 1,606 | Finally, the @OBJECT$ @PREDICAT$ @SUBJECT$ (100 microM) was equipotent to reproterol and DSCG in stabilizing rat mast cells. |
Fact | preserve | 220-229 | 220-229 | T19 | treatment | TREATS | 220 | 229 | preserve | 147-168 | 156-168 | T11 | disodium cromoglycate | OrganicChemical | 147 | 168 | preserve | 233-239 | 233-239 | T15 | asthma | DiseaseOrSyndrome | 233 | 239 | A27 | The beta2-adrenoceptor agonist reproterol and disodium cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively. | 101-328 | 101 | 328 | The beta2-adrenoceptor agonist reproterol and @SUBJECT$ (DSCG) are used in fixed combination for the @PREDICAT$ of @OBJECT$ , because they act on bronchial smooth muscle and inflammatory cells, respectively. |
Fact | preserve | 1317-1324 | 1317-1324 | T102 | inhibit | DISRUPTS | 1,317 | 1,324 | preserve | 1283-1292 | 1283-1292 | T93 | forskolin | BiologicallyActiveSubstance | 1,283 | 1,292 | preserve | 1325-1342 | 1335-1342 | T96 | histamine release | CellFunction | 1,325 | 1,342 | A28 | The potent adenylate cyclase stimulator forskolin (50 microM) was able to inhibit histamine release to a similar extent as DSCG and significantly (P<0.05) enhanced the inhibition of histamine release by DSCG. | 1237-1463 | 1,237 | 1,463 | The potent adenylate cyclase stimulator @SUBJECT$ (50 microM) was able to @PREDICAT$ @OBJECT$ to a similar extent as DSCG and significantly (P<0.05) enhanced the inhibition of histamine release by DSCG. |
Fact | preserve | 1417-1427 | 1417-1427 | T103 | inhibition | DISRUPTS | 1,417 | 1,427 | preserve | 1458-1462 | 1458-1462 | T101 | DSCG | OrganicChemical | 1,458 | 1,462 | preserve | 1437-1454 | 1447-1454 | T100 | histamine release | CellFunction | 1,437 | 1,454 | A29 | The potent adenylate cyclase stimulator forskolin (50 microM) was able to inhibit histamine release to a similar extent as DSCG and significantly (P<0.05) enhanced the inhibition of histamine release by DSCG. | 1237-1463 | 1,237 | 1,463 | The potent adenylate cyclase stimulator forskolin (50 microM) was able to inhibit histamine release to a similar extent as DSCG and significantly (P<0.05) enhanced the @PREDICAT$ of @OBJECT$ by @SUBJECT$ . |
Fact | preserve | 567-569 | 567-569 | T44 | as | same_as | 567 | 569 | preserve | 542-552 | 542-552 | T34 | Reproterol | OrganicChemical | 542 | 552 | preserve | 570-574 | 570-574 | T36 | DSCG | OrganicChemical | 570 | 574 | A30 | Reproterol was as potent as DSCG to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. | 542-644 | 542 | 644 | @SUBJECT$ was as potent @PREDICAT$ @OBJECT$ to inhibit histamine release in rat mast cells (32.8+/-6.0 vs. |
Fact | preserve | 1688-1697 | 1688-1697 | T122 | stabilize | AFFECTS | 1,688 | 1,697 | preserve | 1657-1678 | 1666-1678 | T119 | disodium cromoglycate | OrganicChemical | 1,657 | 1,678 | preserve | 1702-1712 | 1707-1712 | T121 | mast cells | Cell | 1,702 | 1,712 | A31 | In conclusion, reproterol enhances the ability of disodium cromoglycate to stabilize rat mast cells. | 1607-1713 | 1,607 | 1,713 | In conclusion, reproterol enhances the ability of @SUBJECT$ to @PREDICAT$ rat @OBJECT$ . |
Fact | preserve | 267-290 | 284-290 | T21 | bronchial smooth muscle | PART_OF | 267 | 290 | preserve | 277-290 | 284-290 | T17 | smooth muscle | Tissue | 277 | 290 | preserve | 267-276 | 267-276 | T16 | bronchial | BodyPartOrganOrOrganComponent | 267 | 276 | A32 | The beta2-adrenoceptor agonist reproterol and disodium cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on bronchial smooth muscle and inflammatory cells, respectively. | 101-328 | 101 | 328 | The beta2-adrenoceptor agonist reproterol and disodium cromoglycate (DSCG) are used in fixed combination for the treatment of asthma, because they act on @OBJECT$ @PREDICAT$ @SUBJECT$ and inflammatory cells, respectively. |
Fact | preserve | 1047-1054 | 1047-1054 | T75 | inhibit | INHIBITS | 1,047 | 1,054 | preserve | 1015-1025 | 1015-1025 | T65 | salbutamol | OrganicChemical | 1,015 | 1,025 | preserve | 1055-1064 | 1055-1064 | T68 | histamine | NeuroreactiveSubstanceOrBiogenicAmine | 1,055 | 1,064 | A33 | Conversely, the combination of DSCG (1-100 microM) with the beta2-agonist used as reference compound, salbutamol (100 microM) did not inhibit histamine release more than DSCG alone. | 900-1094 | 900 | 1,094 | Conversely, the combination of DSCG (1-100 microM) with the beta2-agonist used as reference compound, @SUBJECT$ (100 microM) did not @PREDICAT$ @OBJECT$ release more than DSCG alone. |
Uncommitted | preserve | 576-578 | 576-578 | T35 | in | TREATS | 576 | 578 | preserve | 496-521 | 512-521 | T29 | enalapril treatment | TherapeuticOrPreventiveProcedure | 496 | 521 | preserve | 589-591 | 589-591 | T34 | MI | DiseaseOrSyndrome | 589 | 591 | A3 | The aim of this work was to study the effect of prolonged ACEI enalapril treatment on systemic arterial structure and elastic properties in rats with MI. | 433-592 | 433 | 592 | The aim of this work was to study the effect of prolonged ACEI @SUBJECT$ on systemic arterial structure and elastic properties @PREDICAT$ rats with @OBJECT$ . |
Fact | preserve | 958-960 | 958-960 | T56 | in | PROCESS_OF | 958 | 960 | preserve | 820-853 | 843-853 | T51 | total peripheral resistance | PhysiologicFunction | 820 | 853 | preserve | 974-978 | 974-978 | T55 | rats | Mammal | 974 | 978 | A4 | At the end of the treatment period, blood pressure, cardiac output, total peripheral resistance, systemic arterial compliance, characteristic impedance, and left ventricular power were measured in anesthetized rats. | 746-979 | 746 | 979 | At the end of the treatment period, blood pressure, cardiac output, @SUBJECT$ , systemic arterial compliance, characteristic impedance, and left ventricular power were measured @PREDICAT$ anesthetized @OBJECT$ . |
Fact | preserve | 227-229 | 227-229 | T17 | in | ASSOCIATED_WITH | 227 | 229 | preserve | 199-209 | 205-209 | T15 | blood flow | OrganismFunction | 199 | 209 | preserve | 230-251 | 241-251 | T16 | myocardial infarction | DiseaseOrSyndrome | 230 | 251 | A5 | Systemic arterial elastic properties, important determinants of left ventricular function and coronary blood flow, are compromised in myocardial infarction (MI). | 89-257 | 89 | 257 | Systemic arterial elastic properties, important determinants of left ventricular function and coronary @SUBJECT$ , are compromised @PREDICAT$ @OBJECT$ (MI). |
Counterfact | preserve | 1711-1717 | 1711-1717 | T94 | affect | AFFECTS | 1,711 | 1,717 | preserve | 1693-1702 | 1693-1702 | T90 | Enalapril | AminoAcidPeptideOrProtein | 1,693 | 1,702 | preserve | 1737-1753 | 1742-1753 | T93 | left ventricular | BodyPartOrganOrOrganComponent | 1,737 | 1,753 | A6 | Enalapril did not affect cardiac output and left ventricular power. | 1693-1760 | 1,693 | 1,760 | @SUBJECT$ did not @PREDICAT$ cardiac output and @OBJECT$ power. |
Fact | preserve | 584-588 | 584-588 | T36 | with | PROCESS_OF | 584 | 588 | preserve | 589-591 | 589-591 | T34 | MI | DiseaseOrSyndrome | 589 | 591 | preserve | 579-583 | 579-583 | T33 | rats | Mammal | 579 | 583 | A7 | The aim of this work was to study the effect of prolonged ACEI enalapril treatment on systemic arterial structure and elastic properties in rats with MI. | 433-592 | 433 | 592 | The aim of this work was to study the effect of prolonged ACEI enalapril treatment on systemic arterial structure and elastic properties in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Uncommitted | preserve | 576-578 | 576-578 | T35 | in | TREATS | 576 | 578 | preserve | 496-521 | 512-521 | T29 | enalapril treatment | TherapeuticOrPreventiveProcedure | 496 | 521 | preserve | 579-583 | 579-583 | T33 | rats | Mammal | 579 | 583 | A8 | The aim of this work was to study the effect of prolonged ACEI enalapril treatment on systemic arterial structure and elastic properties in rats with MI. | 433-592 | 433 | 592 | The aim of this work was to study the effect of prolonged ACEI @SUBJECT$ on systemic arterial structure and elastic properties @PREDICAT$ @OBJECT$ with MI. |
Fact | preserve | 55-59 | 55-59 | T8 | with | PROCESS_OF | 55 | 59 | preserve | 60-87 | 77-87 | T6 | myocardial infarction | DiseaseOrSyndrome | 60 | 87 | preserve | 50-54 | 50-54 | T5 | rats | Mammal | 50 | 54 | A9 | Enalapril improves arterial elastic properties in rats with myocardial infarction. | 0-88 | 0 | 88 | Enalapril improves arterial elastic properties in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1962-1966 | 1962-1966 | T116 | with | USES | 1,962 | 1,966 | preserve | 1942-1961 | 1952-1961 | T107 | long-term treatment | HealthCareActivity | 1,942 | 1,961 | preserve | 1972-1981 | 1972-1981 | T108 | enalapril | AminoAcidPeptideOrProtein | 1,972 | 1,981 | A10 | These results indicate that long-term treatment with ACEI enalapril improves arterial elastic properties through structural modifications of arterial wall in rats with MI. | 1908-2091 | 1,908 | 2,091 | These results indicate that @SUBJECT$ @PREDICAT$ ACEI @OBJECT$ improves arterial elastic properties through structural modifications of arterial wall in rats with MI. |
Fact | preserve | 2083-2087 | 2083-2087 | T118 | with | PROCESS_OF | 2,083 | 2,087 | preserve | 2088-2090 | 2088-2090 | T115 | MI | DiseaseOrSyndrome | 2,088 | 2,090 | preserve | 2078-2082 | 2078-2082 | T114 | rats | Mammal | 2,078 | 2,082 | A11 | These results indicate that long-term treatment with ACEI enalapril improves arterial elastic properties through structural modifications of arterial wall in rats with MI. | 1908-2091 | 1,908 | 2,091 | These results indicate that long-term treatment with ACEI enalapril improves arterial elastic properties through structural modifications of arterial wall in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 47-49 | 47-49 | T7 | in | TREATS | 47 | 49 | preserve | 0-9 | 0-9 | T1 | Enalapril | AminoAcidPeptideOrProtein | 0 | 9 | preserve | 50-54 | 50-54 | T5 | rats | Mammal | 50 | 54 | A12 | Enalapril improves arterial elastic properties in rats with myocardial infarction. | 0-88 | 0 | 88 | @SUBJECT$ improves arterial elastic properties @PREDICAT$ @OBJECT$ with myocardial infarction. |
Fact | preserve | 47-49 | 47-49 | T7 | in | TREATS | 47 | 49 | preserve | 0-9 | 0-9 | T1 | Enalapril | AminoAcidPeptideOrProtein | 0 | 9 | preserve | 60-87 | 77-87 | T6 | myocardial infarction | DiseaseOrSyndrome | 60 | 87 | A13 | Enalapril improves arterial elastic properties in rats with myocardial infarction. | 0-88 | 0 | 88 | @SUBJECT$ improves arterial elastic properties @PREDICAT$ rats with @OBJECT$ . |
Counterfact | preserve | 1711-1717 | 1711-1717 | T94 | affect | AFFECTS | 1,711 | 1,717 | preserve | 1693-1702 | 1693-1702 | T90 | Enalapril | AminoAcidPeptideOrProtein | 1,693 | 1,702 | preserve | 1718-1732 | 1726-1732 | T92 | cardiac output | Finding | 1,718 | 1,732 | A14 | Enalapril did not affect cardiac output and left ventricular power. | 1693-1760 | 1,693 | 1,760 | @SUBJECT$ did not @PREDICAT$ @OBJECT$ and left ventricular power. |
Fact | preserve | 1420-1430 | 1420-1430 | T87 | associated | COEXISTS_WITH | 1,420 | 1,430 | preserve | 1436-1455 | 1448-1455 | T84 | Parkinson's disease | DiseaseOrSyndrome | 1,436 | 1,455 | preserve | 1410-1419 | 1410-1419 | T83 | syndromes | DiseaseOrSyndrome | 1,410 | 1,419 | A1 | Atypical neuroleptic agents and ECT for psychiatric syndromes associated with Parkinson's disease are discussed. | 1352-1470 | 1,352 | 1,470 | Atypical neuroleptic agents and ECT for psychiatric @OBJECT$ @PREDICAT$ with @SUBJECT$ are discussed. |
Fact | preserve | 666-721 | 694-698 | T54 | neurodegenerative disorders such as Parkinson's disease | ISA | 666 | 721 | preserve | 702-721 | 714-721 | T46 | Parkinson's disease | DiseaseOrSyndrome | 702 | 721 | preserve | 666-693 | 684-693 | T45 | neurodegenerative disorders | DiseaseOrSyndrome | 666 | 693 | A2 | The concept of neuroprotection in neurodegenerative disorders such as Parkinson's disease became popular in the mid 1980s and it is hoped that eventually therapy will be directed at slowing progression of the disease. | 626-861 | 626 | 861 | The concept of neuroprotection in @OBJECT$ @PREDICAT$ @SUBJECT$ became popular in the mid 1980s and it is hoped that eventually therapy will be directed at slowing progression of the disease. |
Fact | preserve | 1025-1043 | 1034-1043 | T67 | Surgical therapies | ISA | 1,025 | 1,043 | preserve | 1025-1033 | 1025-1033 | T60 | Surgical | TherapeuticOrPreventiveProcedure | 1,025 | 1,033 | preserve | 1034-1043 | 1034-1043 | T61 | therapies | TherapeuticOrPreventiveProcedure | 1,034 | 1,043 | A3 | Surgical therapies for Parkinson's disease consisting of various forms of lesion surgery as well as stimulation procedures are reviewed. | 1025-1173 | 1,025 | 1,173 | @SUBJECT$ @PREDICAT$ @OBJECT$ for Parkinson's disease consisting of various forms of lesion surgery as well as stimulation procedures are reviewed. |
Fact | preserve | 259-299 | 280-288 | T21 | Levodopa remains the mainstay of therapy | ISA | 259 | 299 | preserve | 259-267 | 259-267 | T19 | Levodopa | AminoAcidPeptideOrProtein | 259 | 267 | preserve | 292-299 | 292-299 | T20 | therapy | TherapeuticOrPreventiveProcedure | 292 | 299 | A4 | Levodopa remains the mainstay of therapy. | 259-300 | 259 | 300 | @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1388-1391 | 1388-1391 | T85 | for | TREATS | 1,388 | 1,391 | preserve | 1384-1387 | 1384-1387 | T81 | ECT | TherapeuticOrPreventiveProcedure | 1,384 | 1,387 | preserve | 1410-1419 | 1410-1419 | T83 | syndromes | DiseaseOrSyndrome | 1,410 | 1,419 | A5 | Atypical neuroleptic agents and ECT for psychiatric syndromes associated with Parkinson's disease are discussed. | 1352-1470 | 1,352 | 1,470 | Atypical neuroleptic agents and @SUBJECT$ @PREDICAT$ psychiatric @OBJECT$ associated with Parkinson's disease are discussed. |
Uncommitted | preserve | 527-537 | 527-537 | T38 | treatments | TREATS | 527 | 537 | preserve | 486-491 | 486-491 | T31 | drugs | PharmacologicSubstance | 486 | 491 | preserve | 542-583 | 576-583 | T36 | newly diagnosed Parkinson's disease | Finding | 542 | 583 | A6 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the drugs should be considered as first line treatments for newly diagnosed Parkinson's disease patients. | 369-593 | 369 | 593 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the @SUBJECT$ should be considered as first line @PREDICAT$ for @OBJECT$ patients. |
Fact | preserve | 542-592 | 584-592 | T39 | newly diagnosed Parkinson's disease patients | PROCESS_OF | 542 | 592 | preserve | 542-583 | 576-583 | T36 | newly diagnosed Parkinson's disease | Finding | 542 | 583 | preserve | 584-592 | 584-592 | T37 | patients | PatientOrDisabledGroup | 584 | 592 | A7 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the drugs should be considered as first line treatments for newly diagnosed Parkinson's disease patients. | 369-593 | 369 | 593 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the drugs should be considered as first line treatments for @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 77-87 | 77-87 | T14 | management | TREATS | 77 | 87 | preserve | 205-212 | 205-212 | T13 | surgery | TherapeuticOrPreventiveProcedure | 205 | 212 | preserve | 91-110 | 103-110 | T7 | Parkinson's disease | DiseaseOrSyndrome | 91 | 110 | A8 | The management of Parkinson's disease has undergone recent changes with the advent of new therapies, both pharmacotherapy and surgery. | 73-213 | 73 | 213 | The @PREDICAT$ of @OBJECT$ has undergone recent changes with the advent of new therapies, both pharmacotherapy and @SUBJECT$ . |
Fact | preserve | 1388-1391 | 1388-1391 | T85 | for | TREATS | 1,388 | 1,391 | preserve | 1361-1379 | 1373-1379 | T80 | neuroleptic agents | PharmacologicSubstance | 1,361 | 1,379 | preserve | 1410-1419 | 1410-1419 | T83 | syndromes | DiseaseOrSyndrome | 1,410 | 1,419 | A9 | Atypical neuroleptic agents and ECT for psychiatric syndromes associated with Parkinson's disease are discussed. | 1352-1470 | 1,352 | 1,470 | Atypical @SUBJECT$ and ECT @PREDICAT$ psychiatric @OBJECT$ associated with Parkinson's disease are discussed. |
Fact | preserve | 77-87 | 77-87 | T14 | management | TREATS | 77 | 87 | preserve | 185-200 | 185-200 | T12 | pharmacotherapy | TherapeuticOrPreventiveProcedure | 185 | 200 | preserve | 91-110 | 103-110 | T7 | Parkinson's disease | DiseaseOrSyndrome | 91 | 110 | A10 | The management of Parkinson's disease has undergone recent changes with the advent of new therapies, both pharmacotherapy and surgery. | 73-213 | 73 | 213 | The @PREDICAT$ of @OBJECT$ has undergone recent changes with the advent of new therapies, both @SUBJECT$ and surgery. |
Fact | preserve | 1563-1565 | 1563-1565 | T94 | in | COEXISTS_WITH | 1,563 | 1,565 | preserve | 1553-1562 | 1553-1562 | T92 | psychosis | MentalOrBehavioralDysfunction | 1,553 | 1,562 | preserve | 1566-1591 | 1584-1591 | T93 | Parkinson's disease | DiseaseOrSyndrome | 1,566 | 1,591 | A11 | Algorithms for the management of early disease as well as the management of psychosis in Parkinson's disease are included. | 1471-1605 | 1,471 | 1,605 | Algorithms for the management of early disease as well as the management of @SUBJECT$ @PREDICAT$ @OBJECT$ are included. |
Fact | preserve | 77-87 | 77-87 | T14 | management | TREATS | 77 | 87 | preserve | 169-178 | 169-178 | T11 | therapies | TherapeuticOrPreventiveProcedure | 169 | 178 | preserve | 91-110 | 103-110 | T7 | Parkinson's disease | DiseaseOrSyndrome | 91 | 110 | A12 | The management of Parkinson's disease has undergone recent changes with the advent of new therapies, both pharmacotherapy and surgery. | 73-213 | 73 | 213 | The @PREDICAT$ of @OBJECT$ has undergone recent changes with the advent of new @SUBJECT$ , both pharmacotherapy and surgery. |
Fact | preserve | 1034-1043 | 1034-1043 | T68 | therapies | TREATS | 1,034 | 1,043 | preserve | 1025-1033 | 1025-1033 | T60 | Surgical | TherapeuticOrPreventiveProcedure | 1,025 | 1,033 | preserve | 1048-1067 | 1060-1067 | T62 | Parkinson's disease | DiseaseOrSyndrome | 1,048 | 1,067 | A13 | Surgical therapies for Parkinson's disease consisting of various forms of lesion surgery as well as stimulation procedures are reviewed. | 1025-1173 | 1,025 | 1,173 | @SUBJECT$ @PREDICAT$ for @OBJECT$ consisting of various forms of lesion surgery as well as stimulation procedures are reviewed. |
Uncommitted | preserve | 527-537 | 527-537 | T38 | treatments | TREATS | 527 | 537 | preserve | 486-491 | 486-491 | T31 | drugs | PharmacologicSubstance | 486 | 491 | preserve | 584-592 | 584-592 | T37 | patients | PatientOrDisabledGroup | 584 | 592 | A14 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the drugs should be considered as first line treatments for newly diagnosed Parkinson's disease patients. | 369-593 | 369 | 593 | New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the @SUBJECT$ should be considered as first line @PREDICAT$ for newly diagnosed Parkinson's disease @OBJECT$ . |
Fact | preserve | 236-239 | 236-239 | T17 | for | TREATS | 236 | 239 | preserve | 228-235 | 228-235 | T13 | surgery | TherapeuticOrPreventiveProcedure | 228 | 235 | preserve | 240-266 | 259-266 | T14 | inflammatory bowel disease | DiseaseOrSyndrome | 240 | 266 | A3 | BACKGROUND: Laparoscopic bowel surgery was evaluated in 44 consecutive patients who underwent surgery for inflammatory bowel disease (IBD). | 128-273 | 128 | 273 | BACKGROUND: Laparoscopic bowel surgery was evaluated in 44 consecutive patients who underwent @SUBJECT$ @PREDICAT$ @OBJECT$ (IBD). |
Fact | preserve | 1289-1291 | 1289-1291 | T74 | in | TREATS | 1,289 | 1,291 | preserve | 1253-1264 | 1253-1264 | T71 | colectomies | TherapeuticOrPreventiveProcedure | 1,253 | 1,264 | preserve | 1307-1310 | 1307-1310 | T73 | IBD | DiseaseOrSyndrome | 1,307 | 1,310 | A4 | CONCLUSIONS: Laparoscopically assisted colectomies can be performed safely in treating IBD. | 1214-1311 | 1,214 | 1,311 | CONCLUSIONS: Laparoscopically assisted @SUBJECT$ can be performed safely @PREDICAT$ treating @OBJECT$ . |
Fact | preserve | 1103-1106 | 1103-1106 | T66 | had | PROCESS_OF | 1,103 | 1,106 | preserve | 1109-1127 | 1120-1127 | T61 | subphrenic abscess | DiseaseOrSyndrome | 1,109 | 1,127 | preserve | 1040-1047 | 1040-1047 | T57 | patient | PatientOrDisabledGroup | 1,040 | 1,047 | A5 | One patient in the laparoscopically assisted colectomy group had a subphrenic abscess that was drained percutaneously, and one patient had a generalized candidiasis. | 1036-1213 | 1,036 | 1,213 | One @OBJECT$ in the laparoscopically assisted colectomy group @PREDICAT$ a @SUBJECT$ that was drained percutaneously, and one patient had a generalized candidiasis. |